Lates News

According to Mei AI News, Huayuan Securities released a research report on April 10, giving Wumei Biology (603983.SH) a "buy" rating. The main reasons for the rating include: 1) The revenue of eye care and skincare products is growing well; 2) The company's net profit margin has slightly decreased, while the sales expense ratio continues to rise. (Daily Economic News)